ORGO vs. FLXN, MDXG, BLTE, PCRX, RCUS, SYRE, ANIP, KNSA, AKRO, and MNKD
Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Flexion Therapeutics (FLXN), MiMedx Group (MDXG), Belite Bio (BLTE), Pacira BioSciences (PCRX), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), Akero Therapeutics (AKRO), and MannKind (MNKD). These companies are all part of the "medical" sector.
Organogenesis (NASDAQ:ORGO) and Flexion Therapeutics (NASDAQ:FLXN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
Organogenesis currently has a consensus price target of $4.83, indicating a potential upside of 75.76%. Given Organogenesis' higher probable upside, equities analysts clearly believe Organogenesis is more favorable than Flexion Therapeutics.
Flexion Therapeutics received 476 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.21% of users gave Organogenesis an outperform vote while only 64.93% of users gave Flexion Therapeutics an outperform vote.
Organogenesis has higher revenue and earnings than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Organogenesis has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Flexion Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Organogenesis has a net margin of 1.34% compared to Flexion Therapeutics' net margin of -100.32%. Organogenesis' return on equity of 2.11% beat Flexion Therapeutics' return on equity.
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 90.0% of Flexion Therapeutics shares are held by institutional investors. 34.0% of Organogenesis shares are held by insiders. Comparatively, 9.1% of Flexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Organogenesis had 2 more articles in the media than Flexion Therapeutics. MarketBeat recorded 2 mentions for Organogenesis and 0 mentions for Flexion Therapeutics. Organogenesis' average media sentiment score of 0.91 beat Flexion Therapeutics' score of 0.00 indicating that Organogenesis is being referred to more favorably in the media.
Summary
Organogenesis beats Flexion Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Organogenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organogenesis Competitors List
Related Companies and Tools
